7 assets in Dyskeratosis Congenita And Related Telomere Biology Disorder

Therapeutic assets addressing Dyskeratosis Congenita And Related Telomere Biology Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Dyskeratosis Congenita And Related Telomere Biology Disorder	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Busulfanum Dyskeratosis Congenita And Related Telomere Biology Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cyclophosphamide Dyskeratosis Congenita And Related Telomere Biology Disorder	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Fludarabine Dyskeratosis Congenita And Related Telomere Biology Disorder	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Melphalan Dyskeratosis Congenita And Related Telomere Biology Disorder	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Rituximab Dyskeratosis Congenita And Related Telomere Biology Disorder	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Tacrolimus Dyskeratosis Congenita And Related Telomere Biology Disorder	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)